ChromaDex Co. (NASDAQ:CDXC - Free Report) - Equities research analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for ChromaDex in a report issued on Monday, March 10th. HC Wainwright analyst R. Selvaraju forecasts that the company will post earnings of $0.03 per share for the quarter. HC Wainwright currently has a "Buy" rating and a $11.00 target price on the stock. The consensus estimate for ChromaDex's current full-year earnings is $0.04 per share. HC Wainwright also issued estimates for ChromaDex's Q2 2025 earnings at $0.04 EPS, Q3 2025 earnings at $0.04 EPS, Q4 2025 earnings at $0.06 EPS, FY2025 earnings at $0.17 EPS, Q1 2026 earnings at $0.05 EPS, Q2 2026 earnings at $0.06 EPS, Q3 2026 earnings at $0.08 EPS, Q4 2026 earnings at $0.11 EPS and FY2026 earnings at $0.29 EPS.
CDXC has been the topic of a number of other reports. LADENBURG THALM/SH SH lifted their price target on ChromaDex from $6.80 to $8.10 and gave the stock a "buy" rating in a research note on Wednesday, March 5th. StockNews.com lowered ChromaDex from a "strong-buy" rating to a "buy" rating in a research note on Thursday, March 6th.
Check Out Our Latest Report on ChromaDex
ChromaDex Price Performance
ChromaDex stock opened at $7.90 on Wednesday. The stock has a market capitalization of $614.23 million, a PE ratio of 790.79 and a beta of 2.21. ChromaDex has a 12 month low of $1.77 and a 12 month high of $9.18. The business has a 50 day simple moving average of $5.87 and a 200-day simple moving average of $5.27.
Institutional Investors Weigh In On ChromaDex
Institutional investors and hedge funds have recently modified their holdings of the company. OneDigital Investment Advisors LLC increased its holdings in ChromaDex by 5.5% during the 3rd quarter. OneDigital Investment Advisors LLC now owns 59,414 shares of the company's stock worth $217,000 after purchasing an additional 3,097 shares during the period. Connor Clark & Lunn Investment Management Ltd. boosted its position in shares of ChromaDex by 10.8% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 175,172 shares of the company's stock worth $639,000 after acquiring an additional 17,115 shares in the last quarter. The Manufacturers Life Insurance Company boosted its position in shares of ChromaDex by 75.4% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 19,732 shares of the company's stock worth $72,000 after acquiring an additional 8,485 shares in the last quarter. Millrace Asset Group Inc. acquired a new position in shares of ChromaDex during the 3rd quarter worth about $93,000. Finally, FMR LLC acquired a new position in shares of ChromaDex during the 3rd quarter worth about $55,000. Hedge funds and other institutional investors own 15.41% of the company's stock.
Insiders Place Their Bets
In other news, Director Frank L. Jaksch, Jr. sold 37,161 shares of the company's stock in a transaction on Friday, December 13th. The stock was sold at an average price of $6.19, for a total value of $230,026.59. Following the transaction, the director now owns 244,179 shares of the company's stock, valued at $1,511,468.01. This represents a 13.21 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 9.64% of the stock is currently owned by corporate insiders.
ChromaDex Company Profile
(
Get Free Report)
ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider ChromaDex, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ChromaDex wasn't on the list.
While ChromaDex currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
